Pulmonx Corporation LUNG
Set alert
As of Nov 2, 11:32 AM ET
- YTD
- +26.47%
- 1 year
- +39.75%
- Open
- 3.04
- Prev close
- 3.01
- Mkt cap
- 120.04M
- Vol
- 565.17K
- Avg vol
- 630.17K
- EPS
- -1.01
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.77
- High
- 3.13
- Forward P/E
- -3.91
- Beta
- 0.68
- Short ratio
- 3.62
- Inst. own
- 94.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 31, 2024
- 50-d avg
- 6.51
- 200-d avg
- 7.33
- 1y target
- 11.92
2Y chart
Events in this range
- Dec 11, 2024Downgrade: Citigroup · Buy → Neutral
- Dec 11, 2024Rating: Wells Fargo · Equal-Weight → Equal-Weight
Signals (80)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| RSI: Overbought | Oct 28, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| RSI: Overbought | Aug 6, 2026 | 2 months ago |
| RSI: Overbought | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | Jun 12, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| RSI: Overbought | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 8, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| SMA: Bullish | Mar 6, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 18, 2026 | 8 months ago |
| RSI: Oversold | Feb 12, 2026 | 8 months ago |
| RSI: Oversold | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 23, 2025 | 10 months ago |
| RSI: Overbought | Dec 19, 2025 | 10 months ago |
| RSI: Overbought | Dec 10, 2025 | 10 months ago |
| SMA: Bullish | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 28, 2025 | 11 months ago |
| SMA: Bearish | Nov 26, 2025 | 11 months ago |
| SMA: Bullish | Nov 25, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 14, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Oct 28, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 28, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 27, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 24, 2025 | 1 year ago |
| SMA: Bearish | Oct 21, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 3, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 21, 2025 | 1 year ago |
| RSI: Oversold | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| RSI: Overbought | Jul 23, 2025 | 1 year ago |
| SMA: Bullish | Jul 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 23, 2025 | 1 year ago |
| RSI: Oversold | May 21, 2025 | 1 year ago |
| MACD: Buy Signal | May 15, 2025 | 1 year ago |
| RSI: Oversold | May 13, 2025 | 1 year ago |
| MACD: Sell Signal | May 1, 2025 | 1 year ago |
| RSI: Oversold | May 1, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 25, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| SMA: Bearish | Mar 25, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 6, 2025 | 1 year ago |
| RSI: Overbought | Feb 20, 2025 | 1 year ago |
| RSI: Overbought | Feb 13, 2025 | 1 year ago |
| SMA: Bullish | Feb 6, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 17, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 23, 2024 | 1 year ago |
Key statistics
- Market cap
- 247.19M
- Enterprise value
- 190.88M
- Trailing P/E
- 0.00
- Forward P/E
- -3.91
- PEG ratio
- 0.00
- Price / sales
- 3.12
- Price / book
- 2.63
- EPS (TTM)
- -1.47
- Beta
- 0.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -72.01%
- Revenue (TTM)
- 79.30M
- Revenue growth
- 15.40%
- Free cash flow
- -14.47M
- Total cash
- 107.78M
- Total debt
- 55.81M
- Return on equity
- -51.99%
- Shares outstanding
- 39.49M
- Short % of float
- 2.92%
- 50-day average
- 6.51
- 200-day average
- 7.33
Analyst view
Consensus: buy
- Target (low)
- 7.50
- Target (mean)
- 11.92
- Target (high)
- 16.00
- Strong buy1
- Buy3
- Hold2
- Sell0
- Strong sell0
Next earnings
Jul 31, 2024
Expected Jul 31, 2024. Consensus EPS estimate -0.44894.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | -0.43 | -0.36 | +0.07 | +16.28% |
| Jul 31, 2024 | Jun 1, 2024 | -0.41 | -0.39 | +0.02 | +4.88% |
| Jul 31, 2024 | Jun 1, 2024 | -0.41 | — | — | — |
| May 1, 2024 | Mar 1, 2024 | -0.43 | -0.36 | +0.07 | +16.28% |
| May 1, 2024 | Mar 1, 2024 | -0.43 | — | — | — |
| Feb 21, 2024 | Dec 1, 2023 | -0.39 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Dec 11, 2024 | Citigroup | down | Buy | Neutral |
| Oct 31, 2024 | Stifel | main | Buy | Buy |
| Aug 1, 2024 | Piper Sandler | main | Overweight | Overweight |
| Aug 1, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 1, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
About Pulmonx Corporation
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- pulmonx.com
News
- All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
- Pulmonx to Participate in Upcoming Investor Conferences
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
- What Pulmonx (LUNG) Said on Its Q3 Earnings Call
- Pulmonx Corporation (LUNG) Q3 2026 Earnings Call Transcript
- Pulmonx Q3 2026 Earnings Call Transcript
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Pulmonx Q3 EPS $(0.19) Beats $(0.26) Estimate, Sales $22.835M Beat $21.944M Estimate
Your note
Sign in to keep a note on LUNG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNS THOMAS WILLIAM | Director | Stock Award(Grant) | Jun 2, 2024 | 36,246 |
| FERRARI RICHARD M | Director | Stock Award(Grant) | Jun 2, 2024 | 57,871 |
| FLORIN DANIEL P | Director | Stock Award(Grant) | Jun 2, 2024 | 56,757 |
| FRENCH GLENDON E III | Director | Sale | Nov 21, 2024 | 1,071,970 |
| LEHMAN DAVID AARON | General Counsel | Sale | Dec 1, 2024 | 197,851 |
| MEAD DANA G JR | Director | Stock Award(Grant) | Jun 2, 2024 | 66,637 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.87% | 5,872,882 | 36.76M | Sep 29, 2024 |
| Primecap Management Company | 14.37% | 5,676,011 | 35.53M | Sep 29, 2024 |
| Morgan Stanley | 9.60% | 3,788,945 | 23.72M | Sep 29, 2024 |
| Blackrock Inc. | 7.08% | 2,795,561 | 17.50M | Sep 29, 2024 |
| Vanguard Group Inc | 5.77% | 2,278,905 | 14.27M | Sep 29, 2024 |
| Deutsche Bank Aktiengesellschaft | 2.84% | 1,121,840 | 7.02M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Primecap Odyssey Aggressive Growth Fund | 9.78% | 3,861,216 | 24.17M | Sep 29, 2024 |
| Fidelity Small Cap Growth Fund | 3.78% | 1,493,472 | 9.35M | Aug 30, 2024 |
| Fidelity Select Portfolios - Pharmaceuticals | 3.63% | 1,431,522 | 8.96M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.94% | 1,161,671 | 7.27M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.48% | 978,930 | 6.13M | Oct 30, 2024 |
| Fidelity Advisor Small Cap Fund | 2.11% | 832,400 | 5.21M | Aug 30, 2024 |